Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 May;57(5):712-7.
doi: 10.1016/j.metabol.2008.01.013.

Efficacy of berberine in patients with type 2 diabetes mellitus

Jun Yin  1 , Huili Xing, Jianping Ye
Affiliations
Randomized Controlled Trial

Efficacy of berberine in patients with type 2 diabetes mellitus

Jun Yin et al. Metabolism. 2008 May.

Abstract

Berberine has been shown to regulate glucose and lipid metabolism in vitro and in vivo. This pilot study was to determine the efficacy and safety of berberine in the treatment of type 2 diabetes mellitus patients. In study A, 36 adults with newly diagnosed type 2 diabetes mellitus were randomly assigned to treatment with berberine or metformin (0.5 g 3 times a day) in a 3-month trial. The hypoglycemic effect of berberine was similar to that of metformin. Significant decreases in hemoglobin A1c (from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01), fasting blood glucose (from 10.6+/-0.9 mmol/L to 6.9+/-0.5 mmol/L, P<.01), postprandial blood glucose (from 19.8+/-1.7 to 11.1+/-0.9 mmol/L, P<.01), and plasma triglycerides (from 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05) were observed in the berberine group. In study B, 48 adults with poorly controlled type 2 diabetes mellitus were treated supplemented with berberine in a 3-month trial. Berberine acted by lowering fasting blood glucose and postprandial blood glucose from 1 week to the end of the trial. Hemoglobin A1c decreased from 8.1%+/-0.2% to 7.3%+/-0.3% (P<.001). Fasting plasma insulin and homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively. Total cholesterol and low-density lipoprotein cholesterol were decreased significantly as well. During the trial, 20 (34.5%) patients experienced transient gastrointestinal adverse effects. Functional liver or kidney damages were not observed for all patients. In conclusion, this pilot study indicates that berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Both berberine and metformin decreased FBG and PBG of type 2 diabetic patients significantly from week 1 to week 13. A, means ± SEM of 15 patients treated with berberine alone. B, means ± SEM of 16 patients treated with metformin alone. C, means ± SEM of 43 patients with combination-therapy including berberine.
See this image and copyright information in PMC

References

    1. Jayaprakasam B, Olson LK, Schutzki RE, et al. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas) J Agric Food Chem. 2006;54:243–8. - PubMed
    1. Matsui T, Ueda T, Oki T, et al. alpha-Glucosidase inhibitory action of natural acylated anthocyanins. 2. alpha-Glucosidase inhibition by isolated acylated anthocyanins. J Agric Food Chem. 2001;49:1952–6. - PubMed
    1. Yin J, Hu R, Chen M, et al. Effects of berberine on glucose metabolism in vitro. Metabolism. 2002;51:1439–43. - PubMed
    1. Yin J, Chen M, Tang J, et al. Effects of berberine on glucose and lipid metabolism in animal experiment. Chinese Journal of Diabetes. 2004;12:215–8.
    1. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256–64. - PubMed

Publication types